Celgene Corporation Announces Changes to Its Board of Directors
April 19 2018 - 7:48AM
Business Wire
Gilla Kaplan, Ph.D., retiring from Board of
Directors after 20 years of service
US health insurance expert Patricia
Hemingway Hall elected to Board of Directors
Juno Therapeutics co-founder and former CEO
Hans Bishop elected to Board of Directors
Celgene Corporation (NASDAQ:CELG) today announced changes to its
Board of Directors. Gilla Kaplan, Ph.D., Celgene’s longest-standing
Director, is retiring from the Board and will not stand for
reelection at the upcoming Annual Meeting of Stockholders to be
held on June 13, 2018. Patricia “Pat” Hemingway Hall and Hans
Bishop have been elected to Celgene’s Board of Directors.
Dr. Kaplan has served as Director since April 1998. She has
provided important scientific perspective and leadership from her
distinguished career in medical research, including her current
role as Director of the Global Health Program for Tuberculosis at
the Bill and Melinda Gates Foundation.
Ms. Hemingway Hall has more than 30 years of experience with a
focus on the US health insurance market. She most recently was CEO
of Health Care Service Corporation (HCSC), the nation’s largest
mutual health insurance company, which operates as Blue Cross and
Blue Shield in Illinois, Montana, New Mexico, Oklahoma and Texas,
from 2008 until her retirement in 2015.
Mr. Bishop is a 30-year industry veteran and was most recently
President and CEO of Juno Therapeutics, a cellular immunotherapy
company that he co-founded in 2013 and led until Juno was acquired
by Celgene in March 2018.
“The changes announced today strengthen corporate governance by
refreshing our Board of Directors and improving strategic insight
provided to management in areas critical to our future success,”
said Mark J. Alles, Chairman and Chief Executive Officer of Celgene
Corporation. “Pat’s deep understanding of the US market access
landscape will help to shape Celgene’s strategy in an increasingly
complex environment. Hans is a pioneer in the field of cellular
immunotherapy whose expertise will help Celgene lead in this
extremely promising area of science.”
“Dr. Kaplan’s contributions to the Celgene Board of Directors
have been invaluable. In addition to her unparalleled scientific
proficiency, she helped guide Celgene’s growth into a global
organization throughout her 20 years as an independent Director. We
thank Dr. Kaplan for her service and wish her all the best,” said
Michael D. Casey, Celgene's Lead Independent Director and Chairman
of the Nominating, Governance & Compliance Committee. “Looking
ahead, Pat and Hans are strategically important additions to the
Board with highly relevant experience in the areas of market access
and cellular immunotherapy.”
About Patricia Hemingway Hall
Patricia “Pat” Hemingway Hall has more than 30 years of
experience with a focus on the US insurance market. Ms. Hemingway
Hall retired as CEO of Health Care Service Corporation (HCSC), the
nation’s largest mutual health insurance company, which operates as
Blue Cross and Blue Shield in Illinois, Montana, New Mexico,
Oklahoma and Texas, in 2015. Previously, Ms. Hemingway Hall served
as President and Chief Operating Officer of HCSC and as President
of Blue Cross and Blue Shield of Texas (BCBSTX). Prior to joining
HCSC in 1993, she held positions at A. Foster Higgins,
Aetna/Partners Health Plans, VHA and Blue Cross and Blue Shield of
Florida. Ms. Hemingway Hall currently serves on the boards of
directors of Manpower Group and Cardinal Health. She earned a
Master’s in Public Health, health planning and administration from
the University of Michigan and a Bachelor of Science in nursing
from Michigan State University.
About Hans Bishop
Hans Bishop is a 30-year industry veteran who founded Juno
Therapeutics in 2013 and served as President and CEO until acquired
by Celgene in March 2018. He served as an Executive in Residence at
Warburg Pincus, a global private equity firm with significant
investment experience in the pharmaceutical and healthcare
industries. Prior to this, he acted as Executive Vice President and
Chief Operating Officer for Dendreon, a Seattle-based biotechnology
company that develops immunotherapy products used in cancer
treatment. He has served as President of Specialty Medicine at
Bayer Healthcare, Senior Vice President of Global Commercial
Operations at Chiron Corporation, and Vice President and General
Manager of European Biopharmaceuticals. Mr. Bishop previously held
various positions at Glaxo Wellcome and SmithKlineBeecham. Mr.
Bishop earned a B.S. in chemistry from Brunel University in
London.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in
the discovery, development and commercialization of innovative
therapies for the treatment of cancer and inflammatory diseases
through next-generation solutions in protein homeostasis,
immuno-oncology, epigenetics, immunology and neuro-inflammation.
For more information, please visit www.celgene.com. Follow Celgene
on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and
YouTube.
Hyperlinks are provided as a convenience and for informational
purposes only. Celgene bears no responsibility for the security or
content of external websites.
Forward-Looking Statement
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual
Report on Form 10-K and our other reports filed with
the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180419005707/en/
CelgeneInvestors:908-673-9628ir@celgene.comorMedia:908-673-2275media@celgene.com
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celgene (NASDAQ:CELG)
Historical Stock Chart
From Apr 2023 to Apr 2024